Zachary Hatch
Psychiatry · Santa Paula, CANPI 1467730614
Payments from drug & device makers
Across 224 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$890
- Otsuka America Pharmaceutical, Inc.$565
- Sunovion Pharmaceuticals Inc.$449
- Tris Pharma Inc$205
- Eisai Inc.$162
- plus $763 from 17 others
What the payments were for
- Food & beverage$4,11899%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $1,131 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $890 |
| Otsuka America Pharmaceutical, Inc. | 27 | $565 |
| Sunovion Pharmaceuticals Inc. | 26 | $449 |
| Tris Pharma Inc | 10 | $205 |
| Eisai Inc. | 10 | $162 |
| Teva Pharmaceuticals USA, Inc. | 6 | $140 |
| Idorsia Pharmaceuticals US Inc | 6 | $120 |
| Alkermes, Inc. | 4 | $85 |
| Merck | 4 | $85 |
| Novo Nordisk | 5 | $84 |
| Biohaven Pharmaceuticals, Inc. | 1 | $30 |
| Lundbeck LLC | 1 | $29 |
| Adlon Therapeutics L.p. | 2 | $27 |
| Lilly USA, LLC | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Verrica Pharmaceuticals Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| GSK | 1 | $11 |
How this compares
$4,165 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 25 | $46,387 |
| RexultiBrexpiprazole | 15 | $29,602 |
| VraylarCariprazine Hcl | 20 | $27,412 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $20,031 |
| Lurasidone Hcl | 26 | $13,150 |
| Lamotrigine ErLamotrigine | 67 | $11,734 |
| Lisdexamfetamine Dimesylate | 27 | $11,699 |
| BelsomraSuvorexant | 11 | $10,669 |
| Aripiprazole | 80 | $8,743 |
| Duloxetine Hcl | 215 | $4,825 |
| Gabapentin | 174 | $4,416 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 76 | $4,247 |
| Trazodone Hcl | 229 | $3,011 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $2,990 |
| Methylphenidate ErMethylphenidate Hcl | 14 | $2,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $890 | $46,38725 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $565 | $29,60215 claims |
| AbbVieVraylar | $1,131 | $27,41220 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $12 | $20,03120 claims |
| MerckBelsomra | $85 | $10,66911 claims |
| Lilly USA, LLCOlanzapine | $25 | $1,36050 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Santa Paula
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.